Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: Development of Diagnostic Tests for Plasmodium falciparum Caused Malaria Only written comments and/or applications for a license, which are received by the NIH Office of Technology Transfer on or before March 25, 2002, will be considered.
View Prospective Grant of Exclusive License: Specific Killing of HIV Infected Lymphocytes by a Recombinant Immunotoxin Directed Against the HIV-1 GP 120 Envelope Glycoprotein Only written comments and/or license applications which are received by the National Institutes of Health on or before March 25, 2002 will be considered.
View Prospective Grant of Co-Exclusive License: “cDNA for Human and Pig Dihydropyrimidine Dehydrogenase' Only written comments and/or license applications which are received by the National Institutes of Health on or before March 4, 2002 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant Of Exclusive License: Prophylactic and/or Therapeutic Vaccines Against HIV and HCV Only written comments and/or applications for a license which are received by NIH on or before February 4, 2002 will be considered.
View National Cancer Institute: PEGylation of Cyanovirin-N for Use in Treating Infectious Diseases Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential CRADA proposals, preferably two pages or less, must be submitted to the NCI within 30 days from date of this publication. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.
View Prospective Grant of Exclusive License: Human Derived Monocyte Attracting Purified Peptide Products for Treating Human Infections and Neoplasms in a Human Body Only written comments and/or license applications which are received by the National Institutes of Health on or before January 28, 2002 will be considered.
View Government-Owned Inventions; Availability for Licensing: Method of Treating HIV With 2′, 3′-Dideoxyinosine (ddI; didanosine)
View Cooperative Research and Development Agreement (CRADA) This opportunity is available until December 10, 2001. Respondents may be provided a longer period of time to furnish additional information if CDC finds this necessary.
View Government-Owned Inventions; Availability for Licensing
View Annual Comprehensive List of Guidance Documents at the Food and Drug Administration We welcome general comments on this list and on agency guidance documents at any time.
View Prospective Grant of Exclusive License: “Analogs of Thalidomide as Potential Angiogenesis Inhibitors” Only written comments and/or license applications which are received by the National Institutes of Health on or before December 17, 2001 will be considered.
View Prospective Grant of Exclusive License: Adeno-Associated Virus with Inverted Terminal Repeat Sequence as Promoter Only written comments and/or applications for a license which are received by NIH on or before November 13, 2001, will be considered.
View National Cancer Institute: Development of Inhibitors of the Hypoxia Inducible Factor (HIF-1) Transcriptional Activation Pathway Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential CRADA proposals, preferably two pages or less, must be submitted to the NCI on or before October 11, 2001. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.
View Prospective Grant of Exclusive License: Veterinary Vaccine Against Escherichia Coli O157 Infection Composed of Detoxified LPS Conjugated to Proteins Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before November 13, 2001 will be considered.
View Prospective Grant of Exclusive License: Virus-Like Particles for the Induction of Autoantibodies Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before November 13, 2001 will be considered.
View Prospective Grant of Exclusive License: Treatment of Cancer, Osteoporosis or any Disease Involving Unwanted or Dysregulated Angiogenesis Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before October 29, 2001 will be considered.
View Prospective Grant of Exclusive License: Melanoma Antigens and Their Use in Diagnostic and Therapeutic Methods, and Identification of TRP-2 as a New Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes Only written comments and/or license applications which are received by the National Institutes of Health on or before October 12, 2001 will be considered.
View Prospective Grant of Exclusive License: Melanoma Antigens and Their Use in Diagnostic and Therapeutic Methods Only written comments and/or license applications which are received by the National Institutes of Health on or before October 12, 2001 will be considered.
View Prospective Grant of Exclusive License: Antibodies and Other Ligands Directed Against KIR2DL4 Receptor For Production of Interferon Gamma Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before October 12, 2001 will be considered.
View National Cancer Institute (NCI); Development of Therapeutic Antibodies and Vaccines From Tumor Associated Antigens in Human Lymphoma Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential, preliminary CRADA proposals, preferably two pages or less, must be submitted to the NCI on or before August 22, 2001. Guidelines for preparing final CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest. CRADA proposals may be accepted after the initial 30 day period if a CRADA Collaborator is not identified from the initial pool of respondents.
View Prospective Grant of Exclusive License: Therapeutic Blockage of ICER Synthesis To Prevent ICER-Mediated Inhibition of Immune Cell Activity Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 21, 2001 will be considered.
View National Cancer Institute: Opportunity for License(s) and/or Cooperative Research and Development Agreement(s) (CRADAs) for the Development of Geldanamycin Analogs for Clinical Use Respondees interested in licensing the invention(s) will be required to submit an "Application for License to Public Health Service Inventions" no later than sixty (60) days from the date of this announcement. Applications submitted thereafter may be considered if a suitable Licensee is not selected from among the timely responses.
View Prospective Grant of Exclusive License: Development of Live, Attenuated Vaccines for Human Use Against Respiratory Syncytial Viruses Types A and B, and Parainfluenza Viruses Types 1, 2 and 3 Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before August 3, 2001 will be considered.
View Prospective Grant of Exclusive License: “Optical Fiber Probe and Methods for Measuring Optical Properties” Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before July 16, 2001 will be considered.